Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori

Johnson, S. A., Ormsby, M. J., McIntosh, A., Tait, S. W.G. , Blyth, K. and Wall, D. M. (2019) Increasing the bactofection capacity of a mammalian expression vector by removal of the f1 ori. Cancer Gene Therapy, 26(7-8), pp. 183-194. (doi: 10.1038/s41417-018-0039-9) (PMID:30100607) (PMCID:PMC6760541)

[img]
Preview
Text
165208.pdf - Published Version
Available under License Creative Commons Attribution.

1MB

Abstract

Bacterial-mediated cancer therapy has shown great promise in in vivo tumour models with increased survival rates post-bacterial treatment. Improving efficiency of bacterial-mediated tumour regression has focused on controlling and exacerbating bacterial cytotoxicity towards tumours. One mechanism that has been used to carry this out is the process of bactofection where post-invasion, bacteria deliver plasmid-borne mammalian genes into target cells for expression. Here we utilised the cancer-targeting Salmonella Typhimurium strain, SL7207, to carry out bactofection into triple negative breast cancer MDA-MB-231 cells. However, we noted that post-transformation with the commonly used mammalian expression vector pEGFP, S. Typhimurium became filamentous, attenuated and unable to invade target cells efficiently. Filamentation did not occur in Escherichia coli-transformed with the same plasmid. Further investigation identified the region inducing S. Typhimurium filamentation as being the f1 origin of replication (f1 ori), an artefact of historic use of mammalian plasmids for single stranded DNA production. Other f1 ori-containing plasmids also induced the attenuated phenotype, while removal of the f1 ori from pEGFP restored S. Typhimurium virulence and increased the bactofection capacity. This work has implications for interpretation of prior bactofection studies employing f1 ori-containing plasmids in S. Typhimurium, while also indicating that future use of S. Typhimurium in targeting tumours should avoid the use of these plasmids.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McIntosh, Ms Anne and Blyth, Professor Karen and Ormsby, Dr Michael and Wall, Dr Daniel and Tait, Professor Stephen and Johnson, Miss Sile
Authors: Johnson, S. A., Ormsby, M. J., McIntosh, A., Tait, S. W.G., Blyth, K., and Wall, D. M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Journal Name:Cancer Gene Therapy
Publisher:Nature Publishing Group
ISSN:0929-1903
ISSN (Online):1476-5500
Published Online:13 August 2018
Copyright Holders:Copyright © 2018 The Authors
First Published:First published in Cancer Gene Therapy 26(7-8): 183-194
Publisher Policy:Reproduced under a Creative Commons License
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
607841Survival and dissemination of enteric pathogens through exploitation and inhibition of programmed cell death pathways in circulating immune cells.Daniel WallBiotechnology and Biological Sciences Research Council (BBSRC)BB/K008005/1III - BACTERIOLOGY
726481Propionic acid use in agriculture and food production is driving evolution of novel Escherichia coli pathotypesDaniel WallBiotechnology and Biological Sciences Research Council (BBSRC)BB/P003281/1III - BACTERIOLOGY
645213Molecular Functions in Disease PhD Studentship (2013-2017)Daniel WallWellcome Trust (WELLCOTR)102460/Z/13/ZIII - BACTERIOLOGY